论文部分内容阅读
据Ｂｉｏｇｅｎ公司报道，肾素Ａ＿１受体抑制剂ＢＧ９７１９（Ａｄｅｎｔｒｉ，ＣＶＴ－１２４）静注用于充血性心衰治疗的Ⅱ期临床研究结果令人鼓舞。公司正计划提前进行第二代心衰治疗候选品种ＢＧ９９２８的临床研究。ＢＧ９９２８可以通过静注或口服给药。Ｂｉｏｇｅｎ公
According to Biogen, the phase II clinical study of intravenous infusion of the renin-A receptor antagonist BG9719 (Adentri, CVT-124) for congestive heart failure has been encouraging. The company is planning to advance the second generation of heart failure treatment candidate BG9928 candidate clinical research. BG9928 can be administered by injection or orally. Biogen male